The research published in Frontiers in Medicine demonstrates the role of inflammasome activation in two of the most common types of JIA, oligo- and poly-articular, which were previously thought to be classical antigen-driven autoimmune conditions. This research provides support for the broad range of conditions that are impacted by activation of the innate immune response and supports the potential of ZyVersa's Inflammasome ASC Inhibitor IC 100 for treating various inflammatory diseases. This positive news may have a short-term positive impact on ZyVersa's stock price.